Comparative Study on the Mode of Action of Vicadrostat and Spironolactone on Protein Profiles and Renal Hemodynamic Effects (COMPARE-VS)

NCT07304817 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

100

Enrollment

OTHER

Sponsor class

Conditions

CKD
Cardiovascular Diseases
Heart Failure

Interventions

DRUG: vicadrostat / empagliflozin combination 1
DRUG: Spironolactone (drug)

Sponsor

University Medical Center Groningen

Collaborators

[object Object]
[object Object]